Form 4: Pfizer SVP & Controller Jennifer B. Damico Reports Acquisition of Phantom Stock Units

Jennifer B. Damico, SVP & Controller of Pfizer Inc., reported the acquisition of 49 phantom stock units through the Pfizer Supplemental Savings Plan on May 15, 2024.

Summary

• On May 15, 2024, Jennifer B. Damico, SVP & Controller of Pfizer Inc., acquired 49 phantom stock units.
• The acquisition was made through the Pfizer Supplemental Savings Plan (SSP).
• Each unit represents one phantom share of common stock.
• The price of the phantom stock units was $28.82.
• Following the transaction, Ms. Damico directly owns 28,346 derivative securities.
• These units are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, reflecting standard insider transaction reporting. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives at publicly traded companies like Pfizer. These transactions are subject to regulatory scrutiny to prevent insider trading.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it involves phantom stock units and not actual shares traded on the open market.

Key Dates